221 results about "Myelin sheaths" patented technology

The invention provides multifunctional hydrogel, drug-loaded hydrogel as well as a preparation method and application of the multifunctional hydrogel and the drug-loaded hydrogel, and belongs to the technical field of biological medicines. According to the multifunctional hydrogel provided by the invention, the gelatin, the transglutaminase and the sulfhydrylated hyaluronic acid are used as preparation raw materials, so that the problem of limited performance of a hydrogel product in the prior art is solved. According to the hydrogel product prepared by the invention, cell adhesion can be provided through a transglutaminase cross-linked gelatin network, meanwhile, an ROS removal effect is provided through a dynamic disulfide bond cross-linked hyaluronic acid network, and degradation of the hydrogel can be regulated and controlled through combination of the two networks; according to the drug-loaded hydrogel provided by the invention, the exosome derived from neural stem cells is additionally encapsulated in the hydrogel, the exosome and the hydrogel jointly achieve the effects of enhancing inhibition of glial scars and resisting inflammation, and the material provided by the invention can promote repair and regeneration of neurons and myelin sheaths, so that the drug-loaded hydrogel can be used for preparing cerebral hemorrhage treatment drugs and can be used for preparing drugs for treating cerebral hemorrhage. And an effective means is provided for the treatment of related diseases.

The present invention relates to a kit of nutrient blend compositions for young individuals, in particular children between 0 and 66 months of age, each of these compositions having age-specific ingredients. The kit of nutrient blend compositions is particularly intended to promote myelination of a targeted brain region, in particular of the social brain, of children at a specific age and brain development stage.

The invention discloses a fusion protein, a fusion protein gene, a recombinant cell, a recombinant antigen, a reagent for detecting an anti-myelin sheath related glycoprotein antibody and a preparation method, a detection method and application of the reagent, the fusion protein is MAG, GlcAT-P and HNK-1ST fusion protein, and the MAG, GlcAT-P and HNK-1ST fusion protein is formed by sequentially connecting MAG, a GGGGS sequence, EGFP, P2A, GlcAT-P, T2A and HNK-1ST; the amino acid sequence of the MAG, GlcAT-P and HNK-1ST fusion protein is as shown in SEQ ID NO. 1; the kit can be used for detecting the MAG autoantibody, has excellent detection sensitivity and specificity, and can ensure the detection accuracy especially for the detection in a low titer range.

Use of human milk oligosaccharides (HMOs) or nutritional compositions comprising human milk oligosaccharides for enhancing executive function in non-infants, preventing and / or reducing the risk of suboptimal executive function in non-infants, managing suboptimal executive function in non-infants, and / or improving myelination to mature the prefrontal cortex region of the brain in non-infants, and the use of synthetic compositions of HMOs and encapsulated products comprising at least 14 individual daily doses of an effective amount of at least one HMO in such applications.

Systems, devices, and methods for using vagus nerve stimulation to treat demyelination disorders and / or disorder of the blood brain barrier are described. The vagus nerve stimulation therapy described herein is configured to reduce or prevent demyelination and / or promote remyelination to treat various disorders related to demyelination, such as multiple sclerosis. A low duty cycle stimulation protocol with a relatively short on-time and a relatively long off-time can be used.

The invention discloses a recombinant protein for detecting an anti-myelin sheath related glycoprotein MAG antibody and a detection reagent of the recombinant protein, and belongs to the technical field of neural immunodiagnostics, five amino acid sites in MAG protein are subjected to specific amino acid point mutation replacement to obtain an MAG protein mutation sequence, the MAG protein mutation sequence is fused with GlcATP enzyme and HNK-1ST enzyme full-length sequences to construct a lentiviral expression vector, and the recombinant protein and the detection reagent are used for detecting the anti-myelin sheath related glycoprotein MAG antibody. According to the present invention, three genes are constructed, and are stably transfected in a host cell so as to stably express the three genes in one cell at the same time, such that the constructed recombinant protein and the wild type MAG protein have similar anti-MAG IgM antibody binding domain, and on the premise of not using GlcATP enzyme and HNK-1ST enzyme small molecule agonists, the sensitivity and the specificity of the detection of the MAG autoimmune antibody by using the CBA method are improved; the method is suitable for preparing related detection reagents for in-vitro detection of the IgM type anti-MAG antibody.

The invention belongs to the technical field of brain dynamics modeling, particularly relates to a regulation and control scheme auxiliary analysis method based on a disease specificity whole brain dynamics model, and aims to realize accurate screening of nerve regulation and control schemes. Comprising the steps that S1, multi-mode magnetic resonance imaging data are obtained and preprocessed, structural connection, a brain region BOLD time sequence, static function connection and dynamic function connection are obtained, and prior constraint values of myelination and cortical atrophy are obtained through calculation based on the preprocessed data; s2, parameterizing the local return coupling strength of the model based on a prior constraint value, coupling the models of different brain regions through the structural connection obtained in the step S1, and constructing a whole brain dynamic model through parameter optimization; s3, training a variational auto-encoder by using different groups of static function connections and dynamic function connections; and S4, applying different regulation and control schemes on the whole brain dynamic model, obtaining a brain state evolution trajectory induced by regulation and control through the trained variational auto-encoder, and screening an effective regulation and control scheme.

A nutritional composition comprising digestible carbohydrates, protein and lipid, wherein the lipid is in the form of lipid globules which are at least partly coated on the surface with phospholipids, for increasing myelination in the brain of an infant who has delayed brain development or is at risk of having delayed brain development.

The invention belongs to the technical field of monoclonal antibody preparation, and particularly relates to a human-mouse chimeric monoclonal antibody for resisting human myelin sheath oligodendrocyte glycoprotein (MOG) and application of the human-mouse chimeric monoclonal antibody. Complementary determining regions in variable regions of a heavy chain and a light chain of the human-mouse chimeric monoclonal antibody of the anti-human MOG protein come from a mouse, parent activity is reserved to the maximum extent, a constant region is a human antibody constant region, immunogenicity is greatly reduced due to introduction of the human antibody constant region, the occurrence probability of a human anti-mouse antibody reaction is reduced, and the anti-human MOG protein is prepared. The specificity of the antibody is improved. The human-mouse chimeric monoclonal antibody resisting the human MOG protein has antigen binding specificity, the heterology of a mouse monoclonal antibody is greatly reduced, the biological activity of the human-mouse chimeric monoclonal antibody is good, and the human-mouse chimeric monoclonal antibody resisting the human MOG protein can specifically detect the MOG protein.

An EAE mouse model proves that the kaempferol and the ephedra, radix aconiti carmichaeli and herba asari particles can obviously save the myelin sheath damage of a mouse. Meanwhile, through serum metabolome analysis and metabolome and transcriptome analysis, the binding force of kaempferol and MMP3 is predicted, and through an EAE mouse model, it is proved that kaempferol can reduce expression of MMP3 through binding with MMP3, and IL-17 and demyelination are inhibited, so that the disease progression of EAE is delayed. Therefore, the invention proves that the kaempferol and the ephedra, monkshood and asarum granules can be used for treating and / or relieving the multiple sclerosis (MS), and the invention provides a new way for the treatment of the multiple sclerosis (MS).

The invention provides a premature infant language development evaluation method, system, equipment and medium, and belongs to the field of applying deep learning to neonatal brain function development disorder screening, and the method comprises the following steps: obtaining a brain image of a neonatal, extracting feature maps of the back curvature, the cortex grey matter thickness, the back depth and the myelin sheath, and obtaining a brain image of the neonatal; dividing the brain image into a plurality of triangular image blocks, and taking the feature maps of the back curvature, the cortex grey matter thickness, the back depth and the myelin sheath as feature channels of each vertex of each triangular image block to obtain feature embedding vectors of the left half brain and the right half brain; inputting the feature embedding vectors of the left half brain and the right half brain into a bidirectional scanning network for forward processing and reverse processing to obtain nonlinear features between the feature embedding vectors of the left half brain and the right half brain, and compressing the nonlinear features to a state space with a fixed size by using a state space model and outputting the nonlinear features. According to the invention, the language development evaluation efficiency of the premature infant can be improved.

The invention discloses a nutritional composition for promoting central nervous system development and application. The invention provides a nutritional composition for promoting the development of a central nervous system. The nutritional composition comprises the following necessary components: a breast milk oligosaccharide component and a casein phosphopeptide component, moreover, in the composition, the mass ratio of the breast milk oligosaccharide component to the casein phosphopeptide component is (1-100): (500-1). According to the invention, the breast milk oligosaccharide component and the casein phosphopeptides are matched to prepare the nutritional composition, and the nutritional composition can significantly promote nerve development such as neuronal maturation, synaptic generation and myelin sheath formation.

The use of α-ketoglutaric acid in the preparation of a drug for preventing and treating demyelination-related diseases. The α-ketoglutaric acid or a derivative thereof is used for preventing and / or treating myelin sheath defects in demyelination-related diseases, such as demyelinating diseases, amyotrophic lateral sclerosis, Huntington's disease, hypomyelinating leukodystrophy, Alzheimer's disease, Parkinson's syndrome and diabetes-related visual impairment, and can promote myelin sheath generation, regeneration or repair, and improve the immune microenvironment in the lesion area.

The invention belongs to the technical field of biomedical materials, and particularly relates to astragaloside-loaded conductive hydrogel as well as a preparation method and application thereof. The preparation method comprises the following steps: uniformly mixing a methylacrylic anhydride gelatin aqueous solution with an organic solvent solution of astragaloside, and carrying out ultraviolet light cross-linking curing to form methylacrylic anhydride gelatin / astragaloside hydrogel; soaking the obtained hydrogel in hydrochloric acid containing a free radical initiator; then soaking and polymerizing in an aniline ethanol solution; and soaking and purifying to obtain the methylacrylic anhydride gelatin-polyaniline conductive hydrogel loaded with astragaloside. In-vitro experiments prove that the compound has a certain anti-inflammatory effect, can induce neural stem cells to be directionally differentiated into neurons and oligodendrocytes, and is beneficial to promoting nerve regeneration and myelin sheath formation; finally, in-vivo experiments prove that the composition can improve the athletic ability and tissue function recovery of SCI rats, and has a good application prospect.

The invention discloses functionalized adhesive hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biomedical materials. The functional adhesive hydrogel is prepared from the following raw materials: recombinant humanized I-type collagen subjected to methacrylation, recombinant humanized I-type collagen modified by N-(2-aminoethyl)-4-(4-(hydroxymethyl)-2-methoxy-5-nitrophenoxy) butyramide, a photoinitiator and water, and the functional adhesive hydrogel is prepared from the following raw materials: recombinant humanized I-type collagen subjected to methacrylation, recombinant humanized I-type collagen modified by N-(2-aminoethyl)-4-(4-(hydroxymethyl)-2-methoxy-5-nitrophenoxy) butyramide, a photoinitiator and water; each milliliter of the functionalized adhesive hydrogel also comprises 80 to 120 U of deoxyribonuclease I, 400 to 600 ng of a clomastine free drug and 5 to 15 [mu] g of a clomastine liposome. The invention also discloses a preparation method and application of the functionalized adhesive hydrogel. The functionalized adhesive hydrogel provided by the invention can reduce secondary injury, inflammatory response and myelin sheath injury of a cerebral hemorrhage part, inhibit formation of neutrophil extracellular traps, and realize multi-level intervention after cerebral hemorrhage.

The invention belongs to the technical field of biological medicine, and particularly relates to a screening method of a recombinant protein for inhibiting the phagocytic function of macrophages on myelin sheath protein and a hydrogel preparation. The invention firstly provides a screening method of the recombinant protein, which comprises the following steps: co-culturing a recombinant protein solution and macrophages in an environment rich in myelin protein, and detecting various indexes to screen out the recombinant protein capable of remarkably inhibiting the phagocytic function of the macrophages on the myelin protein. The invention discloses regulation and control of the macrophage phenotypic change and the relationship between the macrophage phenotypic change and the MD phagocytosis function of the specific recombinant protein for the first time, and provides a new thought for screening the recombinant keratin with a specific function.

The invention discloses a polypeptide Tat-CIRP and application thereof, the amino acid sequence of the polypeptide Tat-CIRP is as shown in SEQ ID NO.3, Tat is a transmembrane structure sequence of 11 amino acids on a Tat protein, and is specifically as shown in SEQ ID NO.1; cIRP is 14 amino acid sequences on a CIRP protein with the highest affinity with GPR68, and is specifically shown as SEQ ID NO. 2. It is found through experimental research that nerve injury and encephaledema after subarachnoid hemorrhage can be remarkably improved through polypeptide Tat-CIRP administration so as to relieve early brain injury, white matter injury is relieved by promoting myelin sheath repair after subarachnoid hemorrhage, and a complete experimental basis is provided for clinical application of the polypeptide Tat-CIRP.

The invention provides application of tea catechin in preparation of a medicine for preventing and treating bortezomib-induced peripheral neuropathy. A plurality of in-vitro model results show that tea catechin can be used as a copper death inhibitor, remarkably improves related indexes of bortezomib-induced peripheral neuropathy, improves survival rates of Schwanton cells and SH-SY5Y, improves mitochondrial functions and cell cycle abnormalities of the Schwanton cells, reduces intracellular copper ion, cuprous ion and ATP levels, and can be used for preparing the copper death inhibitor for the peripheral neuropathy of the Bortezomib-induced peripheral neuropathy of the Bortezomib-induced peripheral neuropathy. Meanwhile, the death of Schwann cells and SH-SY5Y induced by the copper death inducer is reduced. In-vivo experiments show that the tea catechin plays a role in protecting functional damage of the bortezomib, and the tea catechin remarkably improves mechanical hyperalgesia, gait abnormality and pathological changes of myelin sheath and axon of mice caused by peripheral neuropathy induced by the bortezomib. The tea catechin can be used as a medicine for peripheral neuropathy induced by bortezomib, and has high clinical application value and development prospect.

The invention is related with olean-12-en-28-ol, 3β pentacosanoate (OPCA) and its therapeutic effect of olean-12-en-28-ol, 3β pentacosanoate (OPCA) on a Multiple sclerosis (MS).

The present disclosure provides, in one aspect, compounds, compositions, and methods for reducing and / or inhibiting the activity of p38gamma. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for promoting remyelination. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for treating, preventing, and / or ameliorating one or more diseases or disorders in a subject, including but not limited to multiple sclerosis (MS), inflammatory disease, and cancer.

The invention belongs to the technical field of biological medicine, and particularly relates to a single-domain antibody VHH-L1 targeting LINGO-1 protein, and the amino acid sequence of the single-domain antibody VHH-L1 is shown as SEQ ID NO: 1. The single-domain antibody has nanomole-level high affinity and excellent specificity, can effectively block the interaction between LINGO-1 and ligands thereof, and remarkably promotes differentiation and myelination of oligodendroglia cells. The invention further provides a neural stem cell subjected to genetic engineering modification, and the neural stem cell can stably and continuously secrete the single-domain antibody VHH-L1. In a spinal cord injury animal model, the engineered stem cell shows an excellent treatment effect, can significantly promote motor function recovery, axon regeneration and myelin sheath repair, and effectively inhibits glial scar formation. The double advantages of cell therapy and long-acting protein delivery are fused, and a brand new efficient treatment strategy is provided for demyelination diseases such as multiple sclerosis and spinal cord injury.

The present invention relates to a kit of nutrient blend compositions for young individuals, in particular children aged between 0 and 66 months, each one of the compositions having age-specific ingredients. The kit of nutrient blend compositions is specifically aimed at promoting myelination of targeted brain regions, in particular the social brain, of children at specific ages and stages of brain development.

The present disclosure relates to RNA molecules, recombinant nucleic acids and gene therapy vectors for the treatment of diseases and conditions associated with myelination deficiency or dysfunction.

The invention discloses an application of fenoterol hydrobromide and pharmaceutically acceptable salt thereof in preparation of a medicine for treating diabetic peripheral neuropathy. The fenoterol hydrobromide and the pharmaceutically acceptable salt thereof have obvious effects of promoting growth of peripheral sensory neurite and protecting myelin sheath injury, and can improve symptoms of slow nerve conduction speed and sensory deficiency induced by diabetes mellitus.

The present invention relates to nutritional compositions and infant formulas that promote brain myelination. More specifically, the present invention relates to nutritional compositions for infants and young children and related health benefits. In particular, the present invention relates to a nutritional composition comprising a vitamin or a mixture thereof for promoting or supporting an optimal myelination trajectory in the brain, such trajectory being close to the trajectory observed in infants fed only with human breast milk (HBM) several months before life.

The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

A method for determination of an indicator representative of a change in the brain caused by a demyelinating disease, the method including, for each region of interest of the brain, determining a regional coefficient of one of the following diffusion coefficients: the radial diffusion, the axial diffusion, the mean diffusion, the anisotropy fraction, or a combination of several of these coefficients, the regional coefficients being determined from a diffusion MRI image; determining a number of changed regions, for which a condition relating to the value of the regional diffusion coefficient of each region is satisfied; and determining the indicator in accordance with the number of changed regions.

Disclosed herein are methods and compositions for treating a demyelinating disease, such as multiple sclerosis, by administering to a subject suffering from the disease at least one Retinoid X receptor gamma (RXRy) agonist and at least one member selected from a Liver X Receptor (LXR) antagonist, CYP51 inhibitor, TM7SF2 inhibitor, EBP inhibitor, and combinations thereof.

The present invention provides the use of the small molecule compound 2-D08 in the preparation of a drug for treating or preventing demyelinating diseases. As a small molecule compound, 2-D08 has a small molecular weight and is easily permeable through the blood-brain barrier to exert central pharmacodynamic effects. Moreover, the chemical synthesis method of 2-D08 is also very mature, which is conducive to reducing the preparation cost of drugs for treating demyelinating diseases, thereby alleviating the medical expenses of patients to a certain extent. 2-D08 can promote the regeneration of myelin sheaths of spinal cord axons, significantly improve the motor ability and nerve function recovery of mice, and is expected to become a disease-modifying treatment drug targeting the origin of brain damage in MS patients, with brain permeability and ion channel selectivity, and has very broad application prospects.

The invention relates to the technical field of gene engineering, and provides a preparation method and application of a recombinant human myelin sheath oligodendrocyte glycoprotein dominant epitope fusion protein. According to the dominant epitope fusion protein of the recombinant human myelin sheath oligodendrocyte glycoprotein, the dominant epitope fusion protein is an MOG alpha 1 and MOG beta 1 dominant epitope fusion protein, and the amino acid sequence of the MOG alpha 1 and MOG beta 1 dominant epitope fusion protein is shown as SEQ ID NO: 1. According to the technical scheme, the problems of low sensitivity and high omission ratio when the human MOG-IgG antibody is detected in the prior art are solved.